Stock Track | Chemed Plummets 15.96% Intraday on Q4 Earnings Miss, Weak Guidance and Jefferies Price Target Cut
Stock Track
Feb 27
Chemed's stock experienced a significant intraday plummet of 15.96% on Thursday, driven by a combination of disappointing financial results and a negative analyst action.
The sharp decline followed the company's report of declining fourth-quarter earnings that fell short of analyst forecasts. Furthermore, Chemed's 2026 adjusted earnings per share guidance also missed market expectations, signaling potential challenges ahead for the healthcare services provider.
Adding to the negative sentiment, Jefferies cut its price target for Chemed from $475 to $400. Analyst target price reductions often reflect concerns about a company's future valuation and growth prospects, prompting investors to reassess their positions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.